{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:55:34Z","timestamp":1772578534425,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00105-024-05467-9","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:50:42Z","timestamp":1738698642000},"page":"168-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vitiligo\u00a0\u2013 Update zu Pathogenese, Diagnostik und\u00a0Therapie","Vitiligo\u2014update on pathogenesis, diagnostics and therapy"],"prefix":"10.1007","volume":"76","author":[{"given":"Paloma","family":"Seidel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"9988","key":"5467_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V, Whitton\u00a0M, van Geel\u00a0N (2015) Vitiligo. Lancet 386(9988):74\u201384","journal-title":"Lancet"},{"key":"5467_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15503_g","volume-title":"Krankheit Vitiligo \u2013 Ein Positionspapier zur Stigmatisierung, Einschr\u00e4nkung der Lebensqualit\u00e4t und psychosozialen Komorbidit\u00e4t","author":"M B\u00f6hm","year":"2024","unstructured":"B\u00f6hm\u00a0M, Sommer\u00a0R, Gieler\u00a0U, Staubach\u00a0P, Zink\u00a0A, Apfelbacher\u00a0C, Peters\u00a0E (2024) Krankheit Vitiligo \u2013 Ein Positionspapier zur Stigmatisierung, Einschr\u00e4nkung der Lebensqualit\u00e4t und psychosozialen Komorbidit\u00e4t"},{"issue":"3","key":"5467_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","volume":"65","author":"A Alikhan","year":"2011","unstructured":"Alikhan\u00a0A, Felsten\u00a0LM, Daly\u00a0M, Petronic-Rosic\u00a0V (2011) Vitiligo: a\u00a0comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J\u00a0Am Acad Dermatol 65(3):473\u2013491","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5467_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau\u00a0K, Pandya\u00a0AG, Ezzedine\u00a0K, Jones\u00a0H, Gao\u00a0J, Lindley\u00a0A, Harris\u00a0JE (2022) Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J\u00a0Eur Acad Dermatol Venereol 36(10):1831\u20131844","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5467_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.det.2016.11.005","volume":"35","author":"N van Geel","year":"2017","unstructured":"van Geel\u00a0N, Speeckaert\u00a0R (2017) Segmental Vitiligo. Dermatol Clin 35(2):145\u2013150","journal-title":"Dermatol Clin"},{"key":"5467_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/CLEP.S304155","volume":"13","author":"N Mohr","year":"2021","unstructured":"Mohr\u00a0N, Petersen\u00a0J, Kirsten\u00a0N, Augustin\u00a0M (2021) Epidemiology of vitiligo\u2014a dual population-based approach. Clin Epidemiol 13:373\u2013382","journal-title":"Clin Epidemiol"},{"issue":"2","key":"5467_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz\u00a0RA, Andersen\u00a0GHL (2017) Genetics of vitiligo. Dermatol Clin 35(2):245\u2013255","journal-title":"Dermatol Clin"},{"issue":"7","key":"5467_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/jid.2015.25","volume":"135","author":"RY Wagner","year":"2015","unstructured":"Wagner\u00a0RY, Luciani\u00a0F, Cario-Andr\u00e9\u00a0M, Rubod\u00a0A, Petit\u00a0V, Benzekri\u00a0L, Ezzedine\u00a0K, Lepreux\u00a0S, Steingrimsson\u00a0E, Taieb\u00a0A, Gauthier\u00a0Y, Larue\u00a0L, Delmas\u00a0V (2015) Altered E\u2011cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J\u00a0Invest Dermatol 135(7):1810\u20131819","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5467_CR9","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"MK Tulic","year":"2019","unstructured":"Tulic\u00a0MK, Cavazza\u00a0E, Cheli\u00a0Y, Jacquel\u00a0A, Luci\u00a0C, Cardot-Leccia\u00a0N, Hadhiri-Bzioueche\u00a0H, Abbe\u00a0P, Gesson\u00a0M, Sormani\u00a0L, Regazzetti\u00a0C, Beranger\u00a0GE, Lereverend\u00a0C, Pons\u00a0C, Khemis\u00a0A, Ballotti\u00a0R, Bertolotto\u00a0C, Rocchi\u00a0S, Passeron\u00a0T (2019) Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a\u00a0potential initiator of T\u2011cell autoreactivity in vitiligo. Nat Commun 10(1):2178","journal-title":"Nat Commun"},{"issue":"3","key":"5467_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","volume":"140","author":"ML Frisoli","year":"2017","unstructured":"Frisoli\u00a0ML, Harris\u00a0JE (2017) Vitiligo: mechanistic insights lead to novel treatments. J\u00a0Allergy Clin Immunol 140(3):654\u2013662","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5467_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/pcmr.13064","volume":"36","author":"Y Gauthier","year":"2023","unstructured":"Gauthier\u00a0Y, Lepreux\u00a0S, Cario-Andre\u00a0M, Rambert\u00a0J, Dakdaki\u00a0A, Lafon\u00a0M\u2011E, Abouqal\u00a0R, Benzekri\u00a0L (2023) Varicella-zoster virus in actively spreading segmental vitiligo skin: pathological, immunochemical, and ultrastructural findings (a\u00a0first and preliminary study). Pigment Cell Melanoma Res 36(1):78\u201385","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"5467_CR12","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","volume":"25","author":"K Ezzedine","year":"2012","unstructured":"Ezzedine\u00a0K, Lim\u00a0HW, Suzuki\u00a0T, Katayama\u00a0I, Hamzavi\u00a0I, Lan\u00a0CCE, Goh\u00a0BK, Anbar\u00a0T, de Castro\u00a0SC, Lee\u00a0AY, Parsad\u00a0D, van Geel\u00a0N, Le Poole\u00a0IC, Oiso\u00a0N, Benzekri\u00a0L, Spritz\u00a0R, Gauthier\u00a0Y, Hann\u00a0SK, Picardo\u00a0M, Taieb\u00a0A (2012) Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25(3):E1\u2013E13","journal-title":"Pigment Cell Melanoma Res"},{"key":"5467_CR13","doi-asserted-by":"publisher","first-page":"5617838","DOI":"10.1155\/2017\/5617838","volume":"2017","author":"V Vachiramon","year":"2017","unstructured":"Vachiramon\u00a0V, Onprasert\u00a0W, Harnchoowong\u00a0S, Chanprapaph\u00a0K (2017) Prevalence and clinical characteristics of itch in vitiligo and its clinical significance. Biomed Res Int 2017:5617838","journal-title":"Biomed Res Int"},{"issue":"11","key":"5467_CR14","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel\u00a0N, Speeckaert\u00a0R, Ta\u00efeb\u00a0A, Ezzedine\u00a0K, Lim\u00a0HW, Pandya\u00a0AG, Passeron\u00a0T, Wolkerstorfer\u00a0A, Abdallah\u00a0M, Alomar\u00a0A, Bae\u00a0JM, Bekkenk\u00a0M, Benzekri\u00a0L, B\u00f6hm\u00a0M, Eleftheriadou\u00a0V, Esmat\u00a0S, Ghia\u00a0D, Goh\u00a0BK, Grimes\u00a0P, Gupta\u00a0S, Hamzavi\u00a0IH, Harris\u00a0JE, Oh\u00a0SH, Huggins\u00a0R, Katayama\u00a0I, Lan\u00a0E, Lee\u00a0A\u2011Y, Leone\u00a0G, Le Poole\u00a0C, Lui\u00a0H, Maquignon\u00a0N, Meurant\u00a0JM, Monteiro\u00a0P, Oiso\u00a0N, Parsad\u00a0D, Pliszewski\u00a0G, Raboobee\u00a0N, Rodrigues\u00a0M, Rosmarin\u00a0D, Suzuki\u00a0T, Tanemura\u00a0A, Thng\u00a0S, Xiang\u00a0F, Zhou\u00a0Y, Picardo\u00a0M, Seneschal\u00a0J (2023) Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part\u00a01: towards a\u00a0new management algorithm. J\u00a0Eur Acad Dermatol Venereol 37(11):2173\u20132184","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"5467_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee\u00a0JH, Ju\u00a0HJ, Seo\u00a0JM, Almurayshid\u00a0A, Kim\u00a0GM, Ezzedine\u00a0K, Bae\u00a0JM (2023) Comorbidities in patients with vitiligo: a\u00a0systematic review and meta-analysis. J\u00a0Invest Dermatol 143(5):777\u2013789.e6","journal-title":"J Invest Dermatol"},{"issue":"11","key":"5467_CR16","doi-asserted-by":"publisher","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","volume":"15","author":"A Kussainova","year":"2020","unstructured":"Kussainova\u00a0A, Kassym\u00a0L, Akhmetova\u00a0A, Glushkova\u00a0N, Sabirov\u00a0U, Adilgozhina\u00a0S, Tuleutayeva\u00a0R, Semenova\u00a0Y (2020) Vitiligo and anxiety: a\u00a0systematic review and meta-analysis. PLoS ONE 15(11):e241445","journal-title":"PLoS ONE"},{"issue":"3","key":"5467_CR17","doi-asserted-by":"publisher","first-page":"e13418","DOI":"10.1111\/dth.13418","volume":"33","author":"RE Simons","year":"2020","unstructured":"Simons\u00a0RE, Zevy\u00a0DL, Jafferany\u00a0M (2020) Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther 33(3):e13418","journal-title":"Dermatol Ther"},{"key":"5467_CR18","doi-asserted-by":"crossref","unstructured":"Augustin M, Gewiss C, Ben-Anaya N, B\u00f6hm M (2024) Lebensqualit\u00e4t, Krankheitslast und Versorgungsbedarf von Patienten mit Vitiligo. Dermatologie (Heidelb)","DOI":"10.1007\/s00105-024-05312-z"},{"issue":"9","key":"5467_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo\u00a0M, Huggins\u00a0RH, Jones\u00a0H, Marino\u00a0R, Ogunsola\u00a0M, Seneschal\u00a0J (2022) The humanistic burden of vitiligo: a\u00a0systematic literature review of quality-of-life outcomes. J\u00a0Eur Acad Dermatol Venereol 36(9):1507\u20131523","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"5467_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/jdv.14739","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang\u00a0G, Qiu\u00a0D, Yang\u00a0H, Liu\u00a0W (2018) The prevalence and odds of depression in patients with vitiligo: a\u00a0meta-analysis. J\u00a0Eur Acad Dermatol Venereol 32(8):1343\u20131351","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5467_CR21","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/j.jaad.2019.08.064","volume":"83","author":"JM Bae","year":"2020","unstructured":"Bae\u00a0JM, Lee\u00a0RW (2020) 365-nm narrowband Wood\u2019s lamp for vitiligo and hypopigmentation disorders. J\u00a0Am Acad Dermatol 83(4):e283\u2013e284","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5467_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi\u00a0I, Jain\u00a0H, McLean\u00a0D, Shapiro\u00a0J, Zeng\u00a0H, Lui\u00a0H (2004) Parametric modeling of narrowband UV\u2011B phototherapy for vitiligo using a\u00a0novel quantitative tool: the vitiligo area scoring index. Arch Dermatol 140(6):677\u2013683","journal-title":"Arch Dermatol"},{"issue":"5","key":"5467_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","volume":"136","author":"N van Geel","year":"2016","unstructured":"van Geel\u00a0N, Lommerts\u00a0J, Bekkenk\u00a0M, Wolkerstorfer\u00a0A, Prinsen\u00a0CAC, Eleftheriadou\u00a0V, Ta\u00efeb\u00a0A, Picardo\u00a0M, Ezzedine\u00a0K, Speeckaert\u00a0R (2016) Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. J\u00a0Invest Dermatol 136(5):978\u2013984","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5467_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jdv.18593","volume":"37","author":"PV Chernyshov","year":"2023","unstructured":"Chernyshov\u00a0PV, Tomas-Aragones\u00a0L, Manolache\u00a0L, Pustisek\u00a0N, Salavastru\u00a0CM, Marron\u00a0SE, Bewley\u00a0A, Svensson\u00a0A, Poot\u00a0F, Suru\u00a0A, Salek\u00a0SS, Augustin\u00a0M, Szepietowski\u00a0JC, Koumaki\u00a0D, Katoulis\u00a0AC, Sampogna\u00a0F, Abeni\u00a0D, Linder\u00a0DM, Speeckaert\u00a0R, van Geel\u00a0N, Seneschal\u00a0J, Ezzedine\u00a0K, Finlay\u00a0AY (2023) Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts. J\u00a0Eur Acad Dermatol Venereol 37(1):21\u201331","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5467_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1684\/ejd.2018.3449","volume":"28","author":"K-C Fan","year":"2018","unstructured":"Fan\u00a0K\u2011C, Yang\u00a0T\u2011H, Huang\u00a0Y\u2011C (2018) Vitiligo and thyroid disease: a\u00a0systematic review and meta-analysis. Eur J Dermatol 28(6):750\u2013763","journal-title":"Eur J Dermatol"},{"issue":"3","key":"5467_CR26","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Schunter\u00a0JA, Fritz\u00a0K, Salavastru\u00a0C, Dargatz\u00a0S, Augustin\u00a0M, Tanew\u00a0A (2022) S1-Leitlinie: Diagnostik und Therapie der Vitiligo. J\u00a0Dtsch Dermatol Ges 20(3):365\u2013379","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"5467_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00105-015-3717-7","volume":"66","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm\u00a0M (2015) Differenzialdiagnostik der Hypomelanosen. Hautarzt 66(12):945\u2013958","journal-title":"Hautarzt"},{"key":"5467_CR28","doi-asserted-by":"crossref","unstructured":"Seneschal J, Boniface K (2023) Vitiligo: current therapies and future treatments. Dermatol Pract Concept 13(4S2)","DOI":"10.5826\/dpc.1304S2a313S"},{"issue":"16","key":"5467_CR29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG, Grimes\u00a0P, Harris\u00a0JE, Desai\u00a0SR, Lebwohl\u00a0M, Ruer-Mulard\u00a0M, Seneschal\u00a0J, Wolkerstorfer\u00a0A, Kornacki\u00a0D, Sun\u00a0K, Butler\u00a0K, Ezzedine\u00a0K (2022) Two phase\u00a03, randomized, controlled trials of Ruxolitinib cream for vitiligo. N\u00a0Engl J Med 387(16):1445\u20131455","journal-title":"N Engl J Med"},{"key":"5467_CR30","first-page":"1","volume-title":"Thieme Drug Report, Ruxolitinib-Cr\u00e8me \u2013 Behandlungsansatz bei nicht-segmentaler Vitiligo","author":"B Homey","year":"2024","unstructured":"Homey\u00a0B, B\u00f6hm\u00a0M (2024) Thieme Drug Report, Ruxolitinib-Cr\u00e8me \u2013 Behandlungsansatz bei nicht-segmentaler Vitiligo. Thieme, S\u00a01\u201320"},{"issue":"6","key":"5467_CR31","first-page":"337","volume":"103","author":"SK Stacey","year":"2021","unstructured":"Stacey\u00a0SK, McEleney\u00a0M (2021) Topical corticosteroids: choice and application. Am Fam Physician 103(6):337\u2013343","journal-title":"Am Fam Physician"},{"issue":"2","key":"5467_CR32","first-page":"88","volume":"15","author":"B Coskun","year":"2005","unstructured":"Coskun\u00a0B, Saral\u00a0Y, Turgut\u00a0D (2005) Topical 0.05\u202f% clobetasol propionate versus 1\u202f% pimecrolimus ointment in vitiligo. Eur J Dermatol 15(2):88\u201391","journal-title":"Eur J Dermatol"},{"issue":"3","key":"5467_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","volume":"165","author":"N Ho","year":"2011","unstructured":"Ho\u00a0N, Pope\u00a0E, Weinstein\u00a0M, Greenberg\u00a0S, Webster\u00a0C, Krafchik\u00a0BR (2011) A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71\u202f% vs. clobetasol propionate 0\u00b705\u202f% in childhood vitiligo. Br J Dermatol 165(3):626\u2013632","journal-title":"Br J Dermatol"},{"issue":"11","key":"5467_CR34","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal\u00a0J, Speeckaert\u00a0R, Ta\u00efeb\u00a0A, Wolkerstorfer\u00a0A, Passeron\u00a0T, Pandya\u00a0AG, Lim\u00a0HW, Ezzedine\u00a0K, Zhou\u00a0Y, Xiang\u00a0F, Thng\u00a0S, Tanemura\u00a0A, Suzuki\u00a0T, Rosmarin\u00a0D, Rodrigues\u00a0M, Raboobee\u00a0N, Pliszewski\u00a0G, Parsad\u00a0D, Oiso\u00a0N, Monteiro\u00a0P, Meurant\u00a0JM, Maquignon\u00a0N, Lui\u00a0H, Le Poole\u00a0C, Leone\u00a0G, Lee\u00a0A\u2011Y, Lan\u00a0E, Katayama\u00a0I, Huggins\u00a0R, Oh\u00a0SH, Harris\u00a0JE, Hamzavi\u00a0IH, Gupta\u00a0S, Grimes\u00a0P, Goh\u00a0BK, Ghia\u00a0D, Esmat\u00a0S, Eleftheriadou\u00a0V, B\u00f6hm\u00a0M, Benzekri\u00a0L, Bekkenk\u00a0M, Bae\u00a0JM, Alomar\u00a0A, Abdallah\u00a0M, Picardo\u00a0M, van Geel\u00a0N (2023) Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part\u00a02: specific treatment recommendations. J\u00a0Eur Acad Dermatol Venereol 37(11):2185\u20132195","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"5467_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee\u00a0JH, Kwon\u00a0HS, Jung\u00a0HM, Lee\u00a0H, Kim\u00a0GM, Yim\u00a0HW, Bae\u00a0JM (2019) Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a\u00a0systematic review and meta-analysis. JAMA Dermatol 155(8):929\u2013938","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5467_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavali\u00e9","year":"2015","unstructured":"Cavali\u00e9\u00a0M, Ezzedine\u00a0K, Fontas\u00a0E, Montaudi\u00e9\u00a0H, Castela\u00a0E, Bahadoran\u00a0P, Ta\u00efeb\u00a0A, Lacour\u00a0J\u2011P, Passeron\u00a0T (2015) Maintenance therapy of adult vitiligo with 0.1\u202f% tacrolimus ointment: a\u00a0randomized, double blind, placebo-controlled study. J\u00a0Invest Dermatol 135(4):970\u2013974","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5467_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","volume":"38","author":"R Zubair","year":"2020","unstructured":"Zubair\u00a0R, Hamzavi\u00a0IH (2020) Phototherapy for vitiligo. Dermatol Clin 38(1):55\u201362","journal-title":"Dermatol Clin"},{"issue":"2","key":"5467_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaad.2018.10.010","volume":"85","author":"HM Jung","year":"2021","unstructured":"Jung\u00a0HM, Jung\u00a0YS, Lee\u00a0JH, Kim\u00a0GM, Bae\u00a0JM (2021) Antioxidant supplements in combination with phototherapy for vitiligo: a\u00a0systematic review and metaanalysis of randomized controlled trials. J\u00a0Am Acad Dermatol 85(2):506\u2013508","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"5467_CR39","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/jdv.17331","volume":"35","author":"E Fontas","year":"2021","unstructured":"Fontas\u00a0E, Montaudi\u00e9\u00a0H, Passeron\u00a0T (2021) Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a\u00a024-week prospective randomized placebo-controlled study. J\u00a0Eur Acad Dermatol Venereol 35(8):1725\u20131729","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"5467_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamadermatol.2020.5756","volume":"157","author":"HJ Ju","year":"2021","unstructured":"Ju\u00a0HJ, Bae\u00a0JM, Lee\u00a0RW, Kim\u00a0SH, Parsad\u00a0D, Pourang\u00a0A, Hamzavi\u00a0I, Shourick\u00a0J, Ezzedine\u00a0K (2021) Surgical interventions for patients with vitiligo: a\u00a0systematic review and meta-analysis. JAMA Dermatol 157(3):307\u2013316","journal-title":"JAMA Dermatol"},{"issue":"12","key":"5467_CR41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/archderm.138.12.1613","volume":"138","author":"E Balt\u00e1s","year":"2002","unstructured":"Balt\u00e1s\u00a0E, Csoma\u00a0Z, Ign\u00e1cz\u00a0F, Dobozy\u00a0A, Kem\u00e9ny\u00a0L (2002) Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch Dermatol 138(12):1619\u20131620","journal-title":"Arch Dermatol"},{"key":"5467_CR42","doi-asserted-by":"crossref","unstructured":"Fr\u0105czek A, Kasprowicz-Furma\u0144czyk M, Placek W, Owczarczyk-Saczonek A (2022) Surgical treatment of vitiligo. Int J Environ Res Public Health 19(8)","DOI":"10.3390\/ijerph19084812"},{"key":"5467_CR43","doi-asserted-by":"publisher","first-page":"818543","DOI":"10.3389\/fmed.2022.818543","volume":"9","author":"Y Chang","year":"2022","unstructured":"Chang\u00a0Y, Zhang\u00a0S, Zhang\u00a0W, Li\u00a0S, Li\u00a0C (2022) The efficacy and psychoneuroimmunology mechanism of camouflage combined with psychotherapy in vitiligo treatment. Front Med 9:818543","journal-title":"Front Med"},{"issue":"2","key":"5467_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.det.2016.11.010","volume":"35","author":"PE Grimes","year":"2017","unstructured":"Grimes\u00a0PE, Nashawati\u00a0R (2017) Depigmentation Therapies for Vitiligo. Dermatol Clin 35(2):219\u2013227","journal-title":"Dermatol Clin"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05467-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:51:55Z","timestamp":1740412315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05467-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["5467"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05467-9","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"M.\u00a0B\u00f6hm: A.\u00a0Finanzielle Interessen: Vortr\u00e4ge \u00fcber Vitiligo f\u00fcr AbbVie, Incyte, Janssen Cilag, Pfizer.\u00a0\u2013 Beratung zum Thema Vitiligo f\u00fcr AbbVie, Incyte, MSD und Pfizer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt des UKM, Klinik f\u00fcr Hautkrankheiten. P.\u00a0Seidel: A.\u00a0Finanzielle Interessen: Kostenerstattung als passiver Teilnehmer: AbbVie, Almirall, Lilly, UCB.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin am UKM, Klinik f\u00fcr Hautkrankheiten.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}